Marathon's cheap, old steroid breezes through the FDA for Duchenne MD, and gets priced at $89K

Jef­frey Aronin, Marathon

For a sim­ple sys­temic steroid that is cheap and eas­i­ly avail­able out­side the US, de­flaza­cort has re­ceived un­usu­al­ly care­ful sup­port from the FDA, breez­ing through a reg­u­la­to­ry process that has be­dev­iled sev­er­al de­vel­op­ers try­ing to ad­dress the root cause of the dis­ease.

De­flaza­cort won a pri­or­i­ty re­view from the agency as a new ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy — cut­ting four months off the reg­u­la­to­ry process — along with an or­phan drug des­ig­na­tion and rare pe­di­atric dis­ease sta­tus. And to­day, the FDA hand­ed Marathon Phar­ma­ceu­ti­cals a green light to start mar­ket­ing the drug to all boys 5 and old­er whose lives are be­ing slow­ly de­stroyed by the dis­ease.

The cor­ti­cos­teroid will be sold as Em­flaza af­ter one study in­volv­ing 196 DMD pa­tients in­di­cat­ed that it could im­prove the strength of pa­tients with this dis­ease. In an­oth­er tri­al with 29 male pa­tients that last­ed 104 weeks, the FDA re­port­ed, “de­flaza­cort demon­strat­ed a nu­mer­i­cal ad­van­tage over place­bo on an as­sess­ment of av­er­age mus­cle strength.”

The larg­er of those two stud­ies was com­plet­ed 21 years ago, ac­cord­ing to an ab­stract post­ed in Neu­rol­o­gy last year.

For that, the com­pa­ny plans to price the drug at $89,000 a year, ac­cord­ing to the Chica­go Tri­bune, more than $88,oo0 a year more than what Cana­di­ans would pay for the same drug. But like oth­er cas­es in­volv­ing price goug­ing, the com­pa­ny went on to de­fend the price, say­ing that in­sur­ers will cov­er most of the price.

In ad­di­tion to the ap­proval, Marathon wins a rare pe­di­atric dis­ease pri­or­i­ty re­view vouch­er. These vouch­ers have fetched hun­dreds of mil­lions of dol­lars from drug com­pa­nies look­ing for a quick and sure way to slash four months off of one of their own drug re­views.

De­flaza­cort has been avail­able in coun­tries around the world for decades.

Cur­rent­ly, you can buy de­flaza­cort from on­line phar­ma­cies in Cana­da for less than a buck a pill. Un­til fair­ly re­cent­ly it was sold by Shire in the UK, for ex­am­ple, as Cal­cort in 6 mg tablets and used to treat a va­ri­ety of chron­ic au­toim­mune con­di­tions like rheuma­toid arthri­tis. (A spokesper­son for Shire says that the drug changed hands.) But be­cause it’s nev­er been ap­proved in Amer­i­ca, where oth­er steroids have been avail­able for those same con­di­tions, it gets the full reg­u­la­to­ry treat­ment in the US.

One Duchenne mom emailed me to say that she felt her fam­i­ly was be­ing held “hostage” by Marathon, af­ter be­ing able to buy the drug for a thou­sand dol­lars a year. And more crit­i­cism be­gan to sur­face on Fri­day, as the Wall Street Jour­nal re­port­ed that Chris­tine Mc­Sh­er­ry, who runs the non­prof­it Jett Foun­da­tion, said she is “dis­ap­point­ed that Marathon in­creased my cost for the drug by more than $87,000 a year.” A num­ber of pa­tient ad­vo­cates said they were wor­ried es­pe­cial­ly for fam­i­lies with high de­ductible in­sur­ance plans.

De­flaza­cort now joins a list of con­tro­ver­sial meds that have been ac­quired and then sold at an as­tro­nom­i­cal markup. Mar­tin Shkre­li be­came the poster child of the pric­ing de­bate with his 5,000% price hike on Dara­prim, an­oth­er old gener­ic drug that tar­gets a rare con­di­tion, which came with­out any ad­di­tion­al re­search. And ex­ec­u­tives at Valeant and My­lan were hauled in front of law­mak­ers last year and grilled on their own pric­ing tac­tics for ag­ing prod­ucts.

None of it is against the law in the US, though, which is one rea­son why it’s so con­tro­ver­sial. The FDA is re­quired by law to be ag­nos­tic on pric­ing is­sues.

“This is the first treat­ment ap­proved for a wide range of pa­tients with Duchenne mus­cu­lar dy­s­tro­phy,” said Bil­ly Dunn, MD, di­rec­tor of the Di­vi­sion of Neu­rol­o­gy Prod­ucts in the FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search. “We hope that this treat­ment op­tion will ben­e­fit many pa­tients with DMD.”

Up un­til Marathon, though, Duchenne MD has been a com­bat zone at the FDA.

Sarep­ta won a con­tro­ver­sial ap­proval for its DMD drug last year af­ter fight­ing for years to get an OK based on da­ta from a tiny, bad­ly flawed study. Their ap­proval came with a la­bel that tells pa­tients that the com­pa­ny has yet to gain clear ev­i­dence of ef­fi­ca­cy. PTC was shut out, much to their cha­grin. And Bio­Marin‘s dris­apersen was shown the door as well.

Marathon did not re­spond to my queries. The biotech is run by CEO Jef­frey Aronin, who start­ed Ova­tion and sold it to Lund­beck for $900 mil­lion in 2009.

I asked the FDA why the drug war­rant­ed VIP ap­proval. Their re­sponse:

De­flaza­cort has nev­er been ap­proved for any use in the Unit­ed States. Un­der U.S. law, it was re­viewed as a “new drug” and as­sessed for safe­ty and ef­fi­ca­cy for the spe­cif­ic con­di­tions of use in the la­bel­ing (pre­scrib­ing in­for­ma­tion). Ver­sions of de­flaza­cort are avail­able in some coun­tries for oth­er in­di­ca­tions, but not for DMD.  The U.S. ap­proval is the first any­where for DMD. The FDA-ap­proved prod­uct la­bel­ing in­cludes safe­ty and clin­i­cal in­for­ma­tion spe­cif­ic to the drug’s use in DMD.  If a drug meets the statu­to­ry re­quire­ments for or­phan drug des­ig­na­tionex­pe­dit­ed pro­grams, and rare pe­di­atric dis­ease des­ig­na­tion, then a spon­sor is el­i­gi­ble to re­ceive those ben­e­fits.

“We are in a new era in the treat­ment of Duchenne mus­cu­lar dy­s­tro­phy. For the first time, pa­tients in the U.S. with Duchenne will have wide­spread ac­cess to an FDA ap­proved med­i­cine that is in­di­cat­ed for all ge­net­ic forms of the con­di­tion. We are pleased that this de­vel­op­ment will help pa­tients with this dis­ease stay stronger longer,” said Tim­o­thy M. Cun­niff, Pharm.D., Ex­ec­u­tive Vice Pres­i­dent, Re­search & De­vel­op­ment, Marathon Phar­ma­ceu­ti­cals, in a state­ment.

 

Brent Saunders [Getty Photos]

UP­DAT­ED: Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

Brent Saunders has found his way out of the current fix he’s in at Allergan $AGN. He’s selling the company to AbbVie for $63 billion in the latest example of the hot M&A market in biopharma.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Sanofi/Re­gen­eron mus­cle ahead of a ri­val No­var­tis/Roche team, win first ap­proval in key rhi­nos­i­nusi­tis field

Re­gen­eron and their part­ners at Sanofi have beat the No­var­tis/Roche team to the punch on an­oth­er key in­di­ca­tion for their block­buster an­ti-in­flam­ma­to­ry drug Dupix­ent. The drug team scored an ac­cel­er­at­ed FDA ap­proval for chron­ic rhi­nos­i­nusi­tis with nasal polyps, mak­ing this the first such NDA for the field.

An­a­lysts have been watch­ing this race for awhile now, as Sanofi/Re­gen­eron won a snap pri­or­i­ty re­view for what is now their third dis­ease in­di­ca­tion for this treat­ment. And they’re not near­ly done, build­ing up hopes for a ma­jor fran­chise.

Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

Back in 2014, Stephanie Tagliatela opted to take an early exit out of her PhD program after working in Mark Bear’s lab at MIT, where she specialized in the synaptic connections between neuronal cells in the brain. She never finished that PhD, but she and fellow MIT student Kartik Ramamoorthi — who was on the founding team at Voyager — came away with some ideas for a gene therapy startup.

Today, fully 5 years later, she and Ramamoorthi are taking the wraps off of a $104 million mega-round designed to take the cumulative work of their preclinical formative stage for Encoded Therapeutics into human studies. They’ve now raised $158 million since starting out in Illumina’s incubator in the Bay Area, and they believe they are firmly on track to do something unique in gene therapy.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Novotech CEO Dr. John Moller

Novotech CRO Award­ed Frost & Sul­li­van Best Biotech CRO Asia-Pa­cif­ic 2019

Known in the in­dus­try as the Asia-Pa­cif­ic CRO, Novotech is now lead CRO ser­vices provider for the grow­ing num­ber of in­ter­na­tion­al biotechs se­lect­ing the re­gion for their stud­ies.

Re­flect­ing this Asia-Pa­cif­ic growth, Novotech staff num­bers are up 20% since De­cem­ber 2018 to 600 in-house clin­i­cal re­search peo­ple across a full range of ser­vices, across the re­gion.

Novotech’s ca­pa­bil­i­ties have been rec­og­nized by an­a­lysts like Frost & Sul­li­van, most re­cent­ly with the pres­ti­gious Asia-Pa­cif­ic CRO Biotech of the year award for best prac­tices in clin­i­cal re­search for biotechs for the fifth year. See oth­er awards here.

Richard Gonzalez testifying in front of Senate Finance Committee, February 2019 [AP Images]

Ab­b­Vie's $63B buy­out spot­lights the re­turn of ma­jor M&A deals — de­spite the back­lash

Big time M&A is back. But for how long?

Over the past 18 months we’ve now seen three major buyouts announced: Takeda/Shire; Bristol-Myers/Celgene and now AbbVie/Allergan. And with this latest deal it’s increasingly clear that the sharp fall from grace suffered by high-profile players which have seen their share prices blasted has created an opening for the growth players in big pharma to up their game — in sharp contrast to the popular bolt-on deals that have been driving the growth strategy at Novartis, Merck, Roche and others.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

Two biotech uni­corns swell pro­posed IPOs, eye­ing a $600M-plus wind­fall

We’ve been wait­ing for the ar­rival of Bridge­Bio’s IPO to top off the wave of new biotech of­fer­ings sweep­ing through Nas­daq at the end of H1. And now we learn that it’s been sub­stan­tial­ly up­sized.

Ini­tial­ly pen­ciled in at a uni­corn-sized $225 mil­lion, the KKR-backed biotech has spiked that to the neigh­bor­hood of $300 mil­lion, look­ing to sell 20 mil­lion shares at $14 to $16 each. That’s an added 5 mil­lion shares, re­ports Re­nais­sance Cap­i­tal, which fig­ures the pro­posed mar­ket val­u­a­tion for Neil Ku­mar’s com­pa­ny at $1.8 bil­lion.

No­var­tis holds back the copy­cat brigade's at­tack on its top drug fran­chise — for now

A fed­er­al judge has put a gener­ic chal­lenge to No­var­tis’ block­buster mul­ti­ple scle­ro­sis drug Gilenya on hold while a patent fight plays out in court.

Judge Leonard P. Stark is­sued a tem­po­rary in­junc­tion ear­li­er this week, forc­ing My­lan, Dr. Red­dy’s Lab­o­ra­to­ries and Au­robindo Phar­ma to shelve their launch plans to al­low the patent fight to pro­ceed. He ruled that al­low­ing the gener­ics in­to the mar­ket now would per­ma­nent­ly slash the price for No­var­tis, even if it pre­vails. 

Top an­a­lyst finds a sil­ver lin­ing in Ab­b­Vie’s $63B Al­ler­gan buy­out — but there’s a catch

Af­ter get­ting beat up on all sides from mar­ket ob­servers who don’t much care for the lat­est mega-deal to ar­rive in bio­phar­ma, at least one promi­nent an­a­lyst now is start­ing to like what he sees in the num­bers for Ab­b­Vie/Al­ler­gan.

But it’s go­ing to take some en­cour­age­ment if Ab­b­Vie ex­ecs want it to last.

Ab­b­Vie’s mar­ket cap de­clined $20 bil­lion on Tues­day as the stock took a 17% hit dur­ing the day. And SVB Leerink’s Ge­of­frey Porges can see a dis­tinct out­line of an up­side af­ter re­view­ing the fun­da­men­tals of the deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,600+ biopharma pros reading Endpoints daily — and it's free.

While Ako­rn works to re­vive its for­tunes, the FDA hits it with an­oth­er warn­ing let­ter

Ako­rn just can’t dig it­self out of its hole.

The spe­cial­ty gener­ic drug­mak­er has re­ceived yet an­oth­er warn­ing let­ter from the FDA this year. With­out dis­clos­ing any specifics, the Lake For­est, Illi­nois-based drug­mak­er on Wednes­day said the US reg­u­la­tor had is­sued the let­ter, cit­ing an in­spec­tion of its Som­er­set, New Jer­sey man­u­fac­tur­ing fa­cil­i­ty in Ju­ly and Au­gust of 2018. The com­pa­ny’s shares $AKRX dipped about 1.7% to $4.65 be­fore the bell.